Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026. Presentations include three-year follow-up data from patients receiving a one-time… read more.
Eli Lilly and Company announced the FDA approved a label expansion for Zepbound (tirzepatide) to include the four-dose single-patient use KwikPen that delivers a full month of treatment… read more.
Researchers at the University of São Paulo (USP) in Brazil have discovered that two osteoporosis drugs (etidronate and tiludronate) may combat diseases caused by iron accumulation in the… read more.
To be healthy, conventional wisdom tells us to exercise and limit fatty foods. Exercise helps us lose weight and build muscle. It makes our hearts stronger and boosts… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to Jazz Pharmaceuticals Research UK Limited for zanidatamab (Ziihera) in adults to treat biliary tract cancer whose cancer… read more.
An international research group has examined how many people are affected by preclinical and clinical obesity and what health risks are associated with this. The team led by… read more.
Prenatal magnesium sulfate and steroids can reduce the risks of cerebral palsy and respiratory complications in preterm infants. A review in the International Journal of Gynecology & Obstetrics found that… read more.
The EMA’s CHMP adopted a positive opinion, recommending the granting of a conditional marketing authorisation for Kayshild (semaglutide), intended for the treatment of adults with non-cirrhotic metabolic dysfunction-associated… read more.
New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also… read more.
A new study from the Columbia University Mailman School of Public Health identifies team creativity as a powerful, measurable driver of well-being and effectiveness in primary care. The research validates… read more.
Pfizer Inc. announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating Braftovi (encorafenib) in combination with cetuximab… read more.
People who work at night have a higher risk of coronary artery disease, a type of heart disease. A new study suggests that a higher fibre intake in… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
